You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
Using 26 pediatric ependymoma patient samples, researchers sequenced 18,500 single cells to classify and analyze discrete neoplastic subpopulations.
Exome sequencing had lower sensitivity and specificity for finding inborn errors of metabolism than conventional screening, but appeared to refine mass spec-based results.
The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.
The service is the first of its kind in the UK and relies on the Illumina NovaSeq 6000 platform to deliver results.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.